TAK 831

Drug Profile

TAK 831

Alternative Names: TAK-831

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class Antipsychotics
  • Mechanism of Action D amino acid oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Friedreich's ataxia; Schizophrenia
  • Phase I Ataxia

Most Recent Events

  • 22 Dec 2017 Phase-II clinical trials in Schizophrenia (Adjunctive treatment, In adults) in USA (PO)
  • 21 Dec 2017 Phase-II clinical trials in Schizophrenia in United Kingdom (PO) (NCT03359785) (EudraCT2017-001739-38)
  • 21 Dec 2017 Takeda plans a phase II trial for Schizophrenia (Adjunctive treatment) in Europe and North America in December 2017 (NCT03382639)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top